ASSESSMENT OF SAFETY AND FEASIBILITY OF FUS NEXT GENERATION DOME HELMET MEDIATED BLOOD-BRAIN BARRIER DISRUPTION FOR THE TREATMENT OF HIGH-GRADE GLIOMA IN PATIENTS UNDERGOING STANDARD CHEMOTHERAPY

Registry ID

GB-6232

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

SUNNYBROOK RESEARCH INSTITUTE

Start date

2025-06-04

Last update

2024-08-20

Conditions

• GLIOMA

Related clinical trials

• A PHASE II TRIAL OF ACT001 IN CHILDREN AND ADOLESCENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMAS AND H3K27-ALTERED HIGH GRADE GLIOMAS
• A PHASE 1/2 STUDY OF MIRDAMETINIB AND VINBLASTINE FOR NEWLY DIAGNOSED OR PREVIOUSLY UNTREATED PATIENTS WITH PEDIATRIC LOW-GRADE GLIOMA AND ACTIVATION OF THE MAPK PATHWAY
• A PHASE II STUDY EVALUATING THE SAFETY, EFFICACY, AND INTRACRANIAL ACTIVITY OF TARLATAMAB IN RECURRENT/REFRACTORY GLIOMAS WITH IDH MUTATION (TARGID)
• U-R-IMMUNE GLIOMA (CA209-1245): A PILOT STUDY INVESTIGATING UPFRONT ADAPTIVE IMMUNOTHERAPY APPROACH IN CHILDREN, ADOLESCENT AND YOUNG ADULT (CAYA) PATIENTS WITH REPLICATION-REPAIR DEFICIENT (RRD) HIGH-GRADE GLIOMAS (HGG)
• A PILOT STUDY TO INVESTIGATE SAFETY AND EFFICACY OF WEEKLY COMBINATION OF INTRAVENOUS VINBLASTINE WITH ORAL TYPE II RAF INHIBITOR TOVORAFENIB IN PEDIATRIC PATIENTS WITH RECURRENT/PROGRESSIVE RAF ALTERED (NON-NF1) LOW GRADE GLIOMAS
• ONC201 FOR THE TREATMENT OF NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA FOLLOWING COMPLETION OF RADIOTHERAPY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY

View on source registry